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BACKGROUND: No circulating markers are routinely used for renal cancer. The objective of this pilot study was to investigate whether
conditioned media (CM) from renal cancer cell lines contains potential biomarkers that, when measured in clinical fluids, have
diagnostic or prognostic utility.
METHODS: Comparative 2D PAGE profiling of CM from renal cell carcinoma (RCC) and normal renal cultures identified cathepsin D
that was subsequently validated in urine samples from 239 patients and healthy and benign disease subjects.
RESULTS: Urinary cathepsin D was found to be significantly associated with overall (OS) (hazard ratio, HR, 1.33, 95%CI [1.09–1.63],
P¼0.005) and cancer-specific survival (HR 1.36, 95%CI [1.07–1.74], P¼0.013) in RCC patients on univariate analysis. An optimal
cut point (211ngml
 1mmolCr
 1) around which to stratify patients by OS was determined. Five-year OS equal to/above and below
this value was 47.0% (95%CI 35.4%, 62.4%) and 60.9% (48.8%, 76.0%), respectively. On multivariable analysis using pre-operative
variables, cathepsin D showed some evidence of independent prognostic value for OS (likelihood ratio test P-value¼0.056) although
requiring further validation in larger patient numbers with sufficient statistical power to determine independent significance.
CONCLUSION: These data establish an important proof of principle and show the potential of proteomics-based studies. Cathepsin D
may be of value as a pre-operative urinary biomarker for RCC, alone or in combination.
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& 2009 Cancer Research UK
Keywords: renal cell carcinoma; cathepsin D; urine; prognosis; biomarker; proteomics
                                                 
There are approximately 65000 new cases of conventional renal
cell carcinoma (RCC) in Europe each year, resulting in a substan-
tial economic burden (Ferlay et al, 2007; Gupta et al, 2008).
Despite recent advances in our understanding of the underlying
biology, there are still no validated circulating biomarkers of RCC,
which may be of value in diagnosis, prognosis or monitoring
of patients.
Diagnostic markers, obviating the requirement for biopsy, are
desirable, given the increased detection of smaller renal masses, of
which approximately 20–25% are found to be benign (Schachter
et al, 2007). Accurately determining prognosis is important in
defining intensity of treatment and follow-up for individual
patients. Such efforts have traditionally focused on pathological
criteria, based on the surgical specimen (Leibovich et al, 2003;
Sorbellini et al, 2005). However, estimates of risk are relatively
wide for individual patients (Leibovich et al, 2003; Sorbellini et al,
2005) and some elements such as nuclear grade are subject to
intra- and inter-observer variability (Al Aynati et al, 2003). The
possibility of determining outcome pre-operatively has also
recently been highlighted, with the definition of six pre-operative
variables that predict risk of RCC-specific mortality with a high
degree of accuracy (Raj et al, 2008; Karakiewicz et al, 2009). Such
nomograms may influence patient management in terms of
treatment modality, surgical strategy and neoadjuvant treatment
using suninib or sorafenib for example.
Proteomic technologies hold great potential for the identifica-
tion of cancer biomarkers (Koomen et al, 2008). Circulating
protein markers, identified in the blood or urine, could provide
more objective information and pre-operatively. However, analysis
of such fluids for initial biomarker discovery is challenging
because of high salt content, very wide dynamic range of protein
concentrations and dominance by a small number of proteins
present in high concentrations (Hanash et al, 2008). Growth media
conditioned by tumour cells in culture can be used to enrich for
secreted and shed membrane proteins, which may represent
putative circulating markers of disease (Xue et al, 2008). Potential
candidates can then be analysed in urine or blood and clinical
utility assessed. The aim of this study was to carry out a pilot
investigation as to whether this approach would successfully
identify potential markers for renal cancer, which could then be
validated in patient samples for diagnostic or prognostic use and
which could form the basis for more intensive larger-scale studies
subsequently. Received 15 May 2009; revised 14 July 2009; accepted 22 July 2009
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Patient samples
Mid-stream urine samples from 149 untreated patients with clear
cell RCC (before nephrectomy), 30 patients with benign urological
conditions and 60 healthy controls of similar age and sex were
used in the study (Table 1). Immediately post voiding, samples
were collected, placed on ice and pH adjusted to 7.0. One mini
protease inhibitor cocktail tablet (Roche, Burgess Hill, Sussex, UK)
was added per 50ml. The urine was filtered, centrifuged at 2000g
at 41C for 10min, aliquotted and stored at  801C. Samples were
collected following ethical approval between May 1999 and June
2007 at St James’s University Hospital as part of our prospective
sample banking for biomarker studies. All RCC patients except one
(biopsy only) subsequently underwent a nephrectomy. Controls
were matched for similar length of sample storage and age/gender
mix as the patients.
Cell lines and conditioned medium preparation
The human RCC cell lines HTB46, HTB47, HTB49 (ATCC) and
TK10 (NCI Frederick Repository, Washington, USA) were grown
in RPMI 1640 medium (HTB49-MEM alpha)/10% v/v FCS/2mML -
glutamine and maintained at 371C in an humidified incubator with
5% CO2. Ten primary renal cultures (four normal and three
matched normal/tumour pairs) from patients with clear cell RCC
(grades 2–4; stage III/IV) were generated from nephrectomy
samples (normal pole of nephrectomy specimen and areas of
tumour, respectively) and characterised by immunocytochemistry
to confirm epithelial origin as described earlier (Craven et al,
2006b). For this proof of principle study, the strategy involved
comparison by 2D PAGE of conditioned media (CM) from
HTB49 with HTB49 cell lysate to characterise proteins enriched
in CM, which may represent secreted or shed membrane proteins.
HTB49 CM was then compared with a CM pool prepared from four
normal primary cultures to further highlight potential tumour/
normal differences with prioritisation given to those enriched in
CM compared with lysate. It was not possible to use the ideal
choice of primary matched pair cell lines for the discovery
experiments because of limited culture potential and the volumes
of CM needed and this also dictated the use of pooled CM as the
comparator.
For collection of CM, cells were grown to 70–80% confluency,
washed 3  with HBSS and media replaced with serum-free
culture medium supplemented with insulin–transferrin–sodium
selenite (Sigma-Aldrich, Poole, Dorset, UK). After 24h incubation,
which had been shown earlier not to affect cell viability, CM was
collected, placed on ice and filtered through a 0.2mm filter to
remove cell debris. After addition of protease inhibitor (Complete,
Roche; one tablet per 50ml), supernatants (200ml) were concen-
trated using a Gyrosep 300 stirred cell (Intersep, Wokingham,
Berks, UK) pressurised at 4bar with a 10kDa MWCO ultrafiltra-
tion membrane (Millipore, Watford, Herts, UK) with further
concentration to 1ml using a 10kDa MWCO Amicon Ultra
centrifugal filter device (Millipore). The CM was then buffer
exchanged into 2D PAGE lysis buffer [12] and stored at  801C.
2D PAGE analysis
Samples (30mg of protein; triplicate) were subjected to isoelectric
focusing on 18cm pH 3–10 NL IPG strips before separation by
SDS–PAGE (10% polyacrylamide), silver staining and analysis, all
as described earlier (Craven et al, 2006b). Spots upregulated 42-
fold within each cell line-normal culture comparison (Po0.05,
Student’s t-test) were selected for further analysis. For preparative
grade gels, 1mg protein was used and gels were fixed and stained
Table 1 Details of all patients included in the study
N %
Characteristic Normal
Total 60 100
Sex
Male 38 63.3
Female 22 36.7
Age (years)
Median (range) 63 (27, 82)
Benign
Total 30 100
Sex
Male 19 63.3
Female 11 36.7
Age (years)
Median (range) 58 (34, 84)
Condition
Urinary tract infection 4 13
Benign prostatic hypertrophy 3 10
Renal stone 12 40
Cystic disease 4 13
Benign renal tumour
a 62 0
Renal atrophy 1 4
RCC
Total 149 100
Sex
Male 94 63.1
Female 55 36.9
Age (years)
Median (range) 61 (37, 85)
pTumour diameter (cm)
Median (range) 6 (2.0, 15.5)
CT Tumour diameter (cm)
Median (range) 6 (2.0, 21)
Grade
1 3 2.0
2 33 22.2
3 73 49.0
4 40 26.8
Sarcomatoid change
No 137 91.9
Yes 12 8.1
pT stage
1a 31 20.8
1b 32 21.5
2 14 9.4
3a 27 18.1
3b 42 28.2
4 3 2.0
CT T stage
1a 35 27.3
1b 38 29.7
2 31 24.2
3a 19 14.8
4 5 3.9
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swith PlusOne silver stain using a modified protocol compatible
with MS (Yan et al, 2000).
Mass spectrometric sequencing
Excised protein spots were digested with trypsin (Craven et al, 2006b).
Positive-ion MALDI mass spectra were obtained using an Applied Bio-
systems 4700 Proteomics Analyser (Applied Biosystems, Manchester,
UK) in reflectron mode. Final mass spectra were internally calibrated
using tryptic autoproteolysis products or using an internal spike
(angiotensin, 1296.6853). Three to ten of the strongest peaks (S:N
450) in each MS spectrum were selected for CID-MS/MS. The default
calibration was used for MS/MS spectra, which were baseline sub-
tracted and smoothed with peak detection using a minimum S:N of 3
or 5, local noise window of 50 m/z and minimum peak width of 2.9
bins or as described earlier (Craven et al, 2006a). Batch-acquired MS
and MS/MS spectral data were submitted to a combined peptide
mass fingerprint and MS/MS ion search through the Applied
Biosystems GPS Explorer software interface (version 3.5) to
Mascot (Matrix Science Ltd, version 2.2.03, London, UK) with
criteria as described earlier (Vasudev et al, 2008).
Validation of results by western blotting
Samples of CM (5mg) were analysed by western blotting using 10%
acrylamide gels (Craven et al, 2006a). A monoclonal antibody to
cathepsin D (clone 49, BD Biosciences (Oxford, UK); 12.5ngml
 1)
was used and detection performed using mouse EnVision HRP-
conjugated antibody (Dako, Ely, Cambridgeshire, UK; 1:200). In the
absence of a reliable loading control for CM, parallel Coomas-
sie brilliant blue stained gels were used to check for equal loading.
Immunoassay for cathepsin D
Urine was thawed, vortexed and microfuged briefly. An in-house
sandwich ELISA for cathepsin D was developed and validated. All
wash and dilution steps used solution WB (2.5mM NaH2PO4,
7.5mM Na2HPO4, 500mM NaCl/0.1% (v/v) Tween 20, pH7.2)
unless otherwise indicated. Wells (96-well Nunc Maxisorp plates,
VWR, Lutterworth, Leicestershire, UK) were coated with 100mlo f
monoclonal anti-cathepsin D antibody (5mgml
 1; Clone 49) in
sodium phosphate buffer (2.5mM NaH2PO4, 7.5mM Na2HPO4,
0.145 M NaCl, pH 7.2) overnight at 41C and washed 3 . For the
standard curve, human cathepsin D (Sigma-Aldrich) was prepared
in doubling dilutions from 8000ngml
 1 to 500ngml
 1. Diluted
samples (20 ) and standards (100ml) were added to duplicate
wells and incubated at RT for 2h. After washing 5 , 100ml
of rabbit anti-cathepsin D antibody (10.4mgml
 1; Abcam,
Cambridge, UK) in WB/10% (w/v) milk was added to each well
and incubated at RT for 2h. After washing, 100ml of biotinylated
goat anti-rabbit antibody (0.19mgml
 1; Dako) in WB/1% (v/v)
mouse serum was added, plates incubated for 1h, washed and
100ml of HRP-conjugated streptavidin (0.3mgml
 1; Dako) added
to each well. After 30min and a wash step, 100mlo fT M Bs u b s t r a t e
(Sigma-Aldrich) was added and colour development stopped after
20min by addition of 100mlo f0 . 5 M sulphuric acid per well and
absorbance read at 450nm.
Samples were analysed blind, randomised throughout and two
QC samples were included on all plates. Mean intra-assay CVs for
duplicate samples was 12.1% (s.d. 12.4) and mean inter-assay CVs
for the QC samples over five consecutive days was 12.8%. Linearity
was shown on serial dilutions of four samples. Mean recovery
on four urines was 109.3% (s.d. 22.8) for 1500ngml
 1 spikes and
112.1% (s.d. 13.4) for 3000ngml
 1 spikes.
Statistical analysis
Study design and analysis conformed to ReMARK and STARD
guidelines (Bossuyt et al, 2003; McShane et al, 2005). Sample size
was determined for the test of diagnostic potential being powered
to detect a fair diagnostic ability of the marker (power 1-b¼0.90,
significance level of a¼0.05), defined as an AUC of 0.7, such that a
minimum of 33 patients in each group were required (Obuchowski
2000). Receiver operating characteristic (ROC) curve analysis
was performed to test the diagnostic ability of each marker
(Obuchowski 2000). Prognostic value was evaluated as a secondary
investigation where DFS (defined as date of recurrence or
death from any cause), OS and CSS were examined relative
to nephrectomy date. Patients who were still alive or who were
lost to follow-up were censored, as were patients who died
from causes other than RCC in the CSS analysis. To assess the
association of cathepsin D with known prognostic factors, non-
parametric methods of testing for association (Kruskal–Wallis
and Wilcoxon–Mann–Whitney tests), trend (Cuzick’s Wicoxon-
like test) and correlation (Spearman’s rho) were used where
appropriate. Similarly, to assess prognostic ability and the
characteristics of the study population with respect to known
prognostic factors, the Kaplan–Meier estimate of the survival
function, the log rank test and Cox proportional hazards
regression were used. These methods were undertaken using
Stata 9.2 (StataCorp, College Station, TX, USA). To identify the
optimum cut point of cathepsin D for prognosis, an ROC(t) curve
analysis was undertaken (Heagerty et al, 2000).
RESULTS
Comparative analysis of CM
One hundred and thirty-three (13%) protein spots were enriched
in HTB49 CM in comparison to whole cell lysate, with 27
Table 1 (Continued)
N %
Characteristic Normal
N stage
0 132 88.6
1 17 11.4
M stage
0 111 74.5
1 38 25.5
TNM stage
I 58 38.9
II 10 6.7
III 42 28.2
IV 39 26.2
Symptoms
Local 63 43.2
Asymptomatic 49 33.6
Systemic 34 23.3
Relapse
No 76 65.5
Yes 40 34.5
Cancer death
No 112 75.2
Yes 37 24.8
Death from any cause
No 94 63.1
Yes 55 36.9
Abbreviation: RCC¼renal cell carcinoma.
a3 oncocytoma, 1 metanephric adenoma, 1 cystic nephroma, 1 inflammatory
pseudotumour.
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proteins (Table 2), all of which were predicted to undergo
secretion through either classical or non-classical routes (Secreto-
meP and SignalP) (Bendtsen et al, 2004a,b). Gel images and
detailed mass spectrometry data of these and a further 40 proteins
included for reference purposes are provided as Supplementary
data (Supplementary Table 1; Supplementary Figure 1). Compar-
ison of HTB49-derived CM with that from primary normal
renal cultures showed 61 (6%) protein spots upregulated in the
HTB49 sample. After prioritisation on the basis of enrichment
in CM compared with lysate (Table 2), biological relevance,
antibody availability and novelty, cathepsin D (Figure 1) was taken
forward.
Western blot validation
Western blotting confirmed the presence of pro-cathepsin D
(50kDa) in CM from 4/4 established RCC lines, but not the normal
CM. In CM from the three matched primary line pairs, cathepsin D
was detected in only the tumour samples of two pairs and was
absent completely in a third pair (Figure 2A; Supplementary
Figure 2). Before immunoassay development, presence of
mature cathepsin D (34kDa) in urine was confirmed in 4/4
samples from RCC patients and only 1/4 healthy control samples
(Figure 2B).
Immunoassay of urinary cathepsin D
All results were normalised by urinary creatinine. Sample storage
time varied from 2 to 99 months but comparison of a set of 30 ‘old’
and 30 ‘new’ (average 63.4 months vs 7.1 months, respectively)
urines from healthy controls found no significant differences.
Similar comparisons with patient samples were not feasible
Normal pool
33 10 10 pl pl
HTB49
MW(kDa)
200
116
66
55
35
31
21
A
B
Figure 1 Conditioned media analysed by 2D PAGE. (A) A measure of
30mg of HTB49 and pooled normal renal culture CM were separated on
18cm pI 3–10 IPG strips in the first dimension. Each sample was run and
analysed in triplicate and representative gels are shown. (B) The location
of cathepsin D as a cluster of spots is shown, which was enriched in CM
compared with lysate and increased in RCC CM compared with normal
renal primary CM.
Established cell lines
Patient urines
HTB46HTB47 HTB49 TK10 N
Primary cell lines
1
50 kDa
35 kDa
N
T1 T2 T3 T4 N1 N2 N3 N4
TNT NT
23
A
B
Figure 2 Western blot validation of cathepsin D. (A) Samples of CM
(5mg load in each case) were probed for cathepsin D. Expression was seen
in all established cell lines examined but absent in one normal sample
included for comparison purposes. Increased expression by tumour
cultures in two out of three primary tumour (T)/normal (N) matched
pairs was also apparent. Parallel Coomassie staining was performed for
loading control purposes. (B) Urine from four healthy controls and four
patients with RCC were probed for cathepsin D. 15ml of urine was loaded
in each case. Uncropped blots are presented in Supplementary Figure 2.
Table 2 HTB49 CM spot identities
Name Accession no.
No of
spots
No. of
matched peaks
No. of unmatched
peaks % Coverage
MASCOT
Score MSMS Status
IGFBP-rP1 Q16270 1 14 66 45.0 120 SiP
Reticulocalbin 1 precursor Q15293 1 9 42 42.0 80 SiP
w
SPARC P09486 1 9 42 32.0 70 SiP
w
Vimentin P08670 1 35 67 71.0 291 SeP
PAI-1 P05121 4 18 30 49.9 157 2 SiP
Transferrin P02787 8 13 27 30.0 105
Cathepsin D P07339 5 9 28 32.1 83 SiP
w
Nucleobindin 1 Q02818 1 22 56 54.0 172 SiP
BIGH3 Q15582 5 20 33 41.5 166 2 SiP
Complement C3 P01024 1 20 32 23.8 138 SiP
From HTB49 CM, 27 spots (10 proteins) upregulated vs whole cell lysate were identified. Where a protein was found in more than one spot, a representative example of
scores is shown. Confirmation of peptide mass finger printing (PMF) by MS/MS was undertaken for some spots and this is indicated by the number of significant peptides found.
Proteins predicted to contain a signal sequence using SignalP 3.0 are denoted SiP and those predicted to undergo non-classical secretion using SecretomeP are denoted SeP. In
the Status column, proteins marked w indicate those proteins upregulated in comparison to normal conditioned media (CM) (further proteins identified are listed in
Supplementary Table 1).
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severity in such a heterogeneous group and will require future
longitudinal stability studies.
Diagnostic utility A wider range of cathepsin D concentrations
were seen in the RCC group but showed only weak evidence of a
significant difference between groups (P¼0.052 using the
Kruskal–Wallis test; Figure 3; Table 3). ROC analysis showed no
diagnostic utility with area under the curve being 0.5612, 90%
confidence interval (CI) (0.505–0.615) when comparing RCC
patients vs controls (benign and normal).
Association with prognosis Patients with nodal/metastatic disease
or sarcomatoid change had significantly higher median urinary
cathepsin D levels (Table 3). The median length of follow-up
from nephrectomy of those patients still alive was 34 months
(range 0–94 months). The representative nature of the population
was first confirmed by association of survival with grade and
stage (P¼0.001 for both; Figure 4A and B). On univariate analysis
there was evidence of an association between overall survival
and cathepsin D (hazard ratio (HR) 1.33, 95%CI [1.09–1.63],
P¼0.005) that is for every rise of 1 unit on the log 2 scale
(doubling in concentration of cathepsin D), the hazard of dying
increased by 1.3-fold (Figure 4C). There was no evidence of the
proportional hazards assumption being violated using the test of
Grambsch and Therneau (P¼0.208). There was also evidence of
an association between CSS and cathepsin D (HR 1.36, 95%CI
[1.07–1.74], P¼0.013) (Figure 4D), but not with DFS (HR 1.19,
95%CI [0.93–1.52], P¼0.168) – although the estimated HR is
similar.
Using time-dependent ROC curves, the largest AUC(t) was
observed for a cut at 18 months (AUC¼0.712), when comparing
patients who had had an event at 18 months with those who
had not. Examining the points of ROC curve gave a best cut-off
in terms of sensitivity and specificity for cathepsin D of
211ngml
 1mmolCr
 1. The 1-year OS estimates (95%CI) for
o and Xto this cut-off were 95.2% (90.6%, 99.9%) and 80.9%
(71.7%, 91.2%), respectively, with corresponding 5-year estimates
of 60.9% (48.8%, 76.0%) and 47.0% (35.4%, 62.4%) (Figure 4E).
Only 4 patients received adjuvant therapy; 37 patients received IFN
and/or IL-2-based treatment in the metastatic setting; 2 patients
received sunitinib. However, no difference was observed in the
treatment patients received when considered by the cut point for
cathepsin D.
To examine further the utility of urinary cathepsin D as a pre-
operative marker, the association of cathepsin D with the variables
used in the pre-operative nomogram developed by Karakiewicz
et al (n¼2474) (Karakiewicz et al, 2009), that is CT tumour size,
CT T stage and symptoms at presentation was also examined
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Figure 3 Box-plot of urinary cathepsin D normalised to creatinine. The
box extends to the interquartile range (IQR), the line transecting this box
representing the median. The bars extend to 1.5 the IQR and the dots
represent outliers that are beyond these limits.
Table 3 Association of patient and tumour characteristics with urinary
cathepsin D by univariate analysis
Cathepsin D concentration
Status
Median (range)
(ngml
 1lmolCr
 1)
P-value
(association)
P-value
(trend)
Normal 133.2 (40.2, 856.5) 0.052
a
Benign 177.6 (73.9, 536.0)
RCC 178.0 (27.0, 4274.0)
Control 144.3 (40.2, 856.5) 0.113
b
Sex 0.188
Male 145.5 (27.0, 4274.0)
Female 200.0 (40.2, 1209.0)
Age
c 0.103
c 0.212
Grade 0.854 0.577
1or2 195.0 (27.0, 4274.0)
3 178.0 (54.0, 3492.0)
4 172.0 (41.0, 2180.0)
Sarcomatoid change 0.032
No 171.0 (27.0,1789.0)
Yes 380.0 (73.0,2180.0)
pT stage 0.254 0.080
1 172.0 (27.0, 4274.0)
2 175.0 (70.0, 471.0)
3 204.5 (48.0, 3492.0)
4 836.0 (86.0, 1789.0)
CT T stage 0.159 0.086
1 161.0 (27.0, 4274.0)
2 182.0 (27.0, 2180.0)
3 325.0 (48.0, 912.0)
4 139.0 (86.0, 802.0)
N stage 0.001
0 165.0 (27.0, 4274.0)
1/2 362.0 (60.0, 2180.0)
M stage 0.034
0 169.0 (27.0, 4274.0)
1 251.0 (60.0, 1789.0)
Overall stage 0.216 0.043
I 165.0 (27.0,4274.0)
II 175.0 (70.0,376.0)
III 164.5 (48.0,3492.0)
IV 224.0 (60.0,1789.0)
Symptoms 0.368 0.190
Local 169.0 (27.0,4274.0)
Asymptomatic 172.0 (33.0,3492.0)
Systemic 226.5 (63.0,912.0)
Tumour size
c
CT 0.143
c 0.109
pathology 0.115
c 0.173
aRefers to test comparing normal, benign and renal cell carcinoma (RCC) group.
bRefers to test comparing control (normal and benign) with RCC group.
cSpearman’s
rank correlation coefficient. Age, sex and tumour-related factors relate to RCC group
only. P-value (association) is result of test comparing distributions in groups under null
hypothesis of them being identical and P-value (trend) is the result of a test under the
null hypothesis of no trend in naturally ordinal groups.
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increasing cathepsin D concentration and CT T stage (P¼0.086)
was observed when using the non-parametric trend test (con-
firmed by examining medians in Table 3).
On multivariable analysis, using these pre-operative variables
and considering OS, cathepsin D showed some evidence of inde-
pendent prognostic value (likelihood ratio test (LRT) P-value¼
0.056; Table 4). No evidence was observed for association of
cathepsin D with CSS (LRT P¼0.291) or DFS (LRT P¼0.103).
Metastatic disease, sex, and CT T stage showed independently
prognostic value (Po0.050), and for other variables HRs were
within the 95% CIs reported earlier in a much larger dataset
(Karakiewicz et al, 2009). The power to show independent
prognostic value in this pilot study is low as there are a large
number of variables included in the model (nine when considering
all levels in categorical variables) and simulation experiments
based on this model show that 200 patients would be required at
observed event rates to attain a power of approximately 50% and
500 patients to attain a power of approximately 90% with similar
HRs to those observed at standard significance levels (Cairns et al,
in preparation). Hence, a larger study would be required to show
strong evidence of an independent prognostic association with
cathepsin D.
DISCUSSION
In this pilot study, we have shown that proteomic analysis of CM
from renal cancer cell lines, as described in other diseases (Xue et al,
2008), may result in the identification of potential biomarkers such
as cathepsin D. Furthermore, although samples from 149 patients
with RCC were included, this represents a relatively small validation
study with only moderate statistical power for a potential marker
with this magnitude of HR, and yet we were able to show the novel
finding of an association between urinary cathepsin D in RCC and
survival, which has potential clinical application.
Cathepsin D is a lysosomal protease, synthesised as a pre-
pro-enzyme. Removal of the signal peptide yields 52kDa pro-
cathepsin D, which undergoes N-glycosylation and is then targeted
to the lysosome to yield a mature two-chain enzyme consisting
of a light (14kDa) amino-terminal domain and a heavy (34kDa)
carboxyl-terminal domain. The greater amounts of pro-cathepsin
D present in RCC CM do not reflect increased transcription (data
not shown) but may be translation-related or occur from re-
routing of the protein. Such aberrant secretion is present in many
cancer types (Liaudet-Coopman et al, 2006), in a number of
different glycoforms (Capony et al, 1989), which may account
for the cluster of spots represented by the protein in this study.
Pro-cathepsin D is known to function as a mitogen, acting entirely
independently of its proteolytic activity (Vetvicka et al, 2000;
Vashishta et al, 2006), although the mechanism mediating these
effects is yet to be understood. On the basis of characterisation of
the reactivity of the antibodies used in our ELISA, it is likely that
the assay measures both precursor and mature forms.
Our current findings are thus biologically plausible. Cathepsin D
levels were associated with established features of tumour aggres-
siveness, such as positive lymph nodes, sarcomatoid change and
metastatic disease at presentation as well as CT-defined tumour
and overall stage. Increased tissue expression of cathepsin D
has been correlated with poorer outcome in a number of other
cancers, although inconsistently (Harris et al, 2007). In RCC, high
expression was associated with a significantly improved OS
compared with low expressers (82 vs 53 months; P¼0.03) with
independent prognostic significance (Merseburger et al, 2005).
Tissue cathepsin D did not correlate with tumour characteristics,
unlike urinary cathepsin D in our study. These findings seem to
contradict our own, but intra-cellular levels of cathepsin D may
bear little correlation to the proportion/form of cathepsin D that is
externalised. Indeed, unlike tissue, serum cathepsin D levels do not
differ between RCC patients and healthy controls (Merseburger
et al, 2007). Similarly, no diagnostic utility for urinary cathepsin D
was found in this study. The source of cathepsin D in healthy
control urine is uncertain, but is not thought to originate from
serum because differences in glycoforms are apparent (Zuhlsdorf
et al, 1983) and may reflect release from urothelial cells on
turnover.
Urine is accessible but its composition is influenced by many
factors such as sex, age, diet, concomitant renal disease and
medications, potentially affecting the interpretation of any given
test (Barratt and Topham, 2007). However, urinary cancer markers
are available and approved by the FDA as exemplified by nuclear
matrix protein 22 for bladder cancer. This study illustrates the
principle of using CM as an initial source for biomarker discovery,
with validation subsequently in biological fluids such as urine.
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Figure 4 Grade, stage, urinary cathepsin D and survival. Overall survival
curves based on (A) tumour grade and (B) stage validate our patient
population. (C) Overall and (D) cancer-specific survival, respectively, by
urinary cathepsin D concentration (normalised for creatinine) considered
as quartiles. (E) Overall survival based on the optimal cut point of
211ngml
 1mmolCr
 1 cathepsin D, determined by time-dependent ROC
analysis.
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sFuture work will include increasing the number of cell lines
profiled to allow systematic prioritisation of candidate markers
based on conserved changes, and increasing the depth of coverage
to find potentially more discriminant markers. The potential utility
of cathepsin D as a pre-operative marker needs to be explored
further using a much larger sample bank to allow a sufficiently
powered study for determination of independent prognostic ability
and if positive, the inclusion in prognostic models examined. In
addition, the relationship between urinary and tissue levels of
cathepsin D and the various forms will be investigated with our
own work with cell lines indicating a VHL-based regulation of
expression (data not shown).
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